Exelixis
EXEL
#1697
Rank
S$13.39 B
Marketcap
$46.90
Share price
0.52%
Change (1 day)
65.23%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : S$1.60 Billion

According to Exelixis's latest financial reports the company has S$1.60 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31S$1.31 B-25.06%
2022-12-31S$1.75 B-11.56%
2021-12-31S$1.98 B24.26%
2020-12-31S$1.59 B38.92%
2019-12-31S$1.14 B21.3%
2018-12-31S$0.94 B82.63%
2017-12-31S$0.51 B-14.64%
2016-12-31S$0.60 B157.11%
2015-12-31S$0.23 B23.95%
2014-12-31S$0.19 B-37.94%
2013-12-31S$0.30 B-38.95%
2012-12-31S$0.50 B100%
2011-12-31S$0.25 B20.07%
2010-12-31S$0.20 B-26.51%
2009-12-31S$0.28 B-24.02%
2008-12-31S$0.37 B-3.97%
2007-12-31S$0.39 B42.45%
2006-12-31S$0.27 B10.84%
2005-12-31S$0.24 B-2.25%
2004-12-31S$0.25 B-37.15%
2003-12-31S$0.40 B4.58%
2002-12-31S$0.38 B-8.62%
2001-12-31S$0.42 B116.09%
2000-12-31S$0.19 B1597.95%
1999-12-31S$11.48 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
S$5.78 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$9.80 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
S$19.65 B 1,127.17%๐Ÿ‡บ๐Ÿ‡ธ USA
S$10.89 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
S$12.13 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
S$27.33 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
S$13.40 B 736.89%๐Ÿ‡บ๐Ÿ‡ธ USA
S$38.18 M-97.62%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.10 B-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA